Medical AI firm Echo IQ Limited (ASX: EIQ) entered an ASX trading halt on September 7, 2026.
The company requested the pause pending a significant announcement regarding its EchoSolv HF heart failure diagnostic. This update will outline the regulatory pathway critical for the product's commercialization plans.
Echo IQ previously secured FDA 510(k) clearance in the United States for its EchoSolv AS aortic stenosis product. The current trading halt remains in effect until the announcement is released or September 9, 2026.